Komori
Business alliance4882Perseus Proteomics Inc.Pharmaceuticals

Notice of the Execution of a Memorandum of Understanding with EirGenix, Inc. to Explore Collaboration on Antibody Drugs

We entered into a non-binding memorandum of understanding with Taiwan-based EirGenix, Inc. to discuss and explore collaboration and business opportunities related to the research, development and manufacturing of antibody drugs. No specific transaction or collaboration has been decided at this time.

Worth reading
33Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Avoiding a definitive answer
How definitive the wording is.

Agreements reached under this partnership

Business alliance
4882Perseus Proteomics Inc.
Alliance partnerEirGenix, Inc.
Details of the alliance
  1. 1

    Collaboration related to antibody research, development and contract manufacturing

  2. 2

    Mutual exploration of business opportunities

These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.

About the partner
Business DescriptionResearch and development of biopharmaceuticals and contract development and manufacturing organization (CDMO) services
LocationTaiwan, New Taipei City
Impact on Business Performance

The execution of this memorandum of understanding has no impact on the Company's financial results at this time.

Agreements reached under this partnership
ItemDetails
Name of alliance partnerEirGenix, Inc.
Alliance partner's business activitiesResearch and development of biopharmaceuticals and contract development and manufacturing organization (CDMO) services
Alliance partner's locationTaiwan, New Taipei City
Type of allianceBusiness alliance
Details of the allianceCollaboration related to antibody research, development and contract manufacturing, Mutual exploration of business opportunities
Impact on Business PerformanceThe execution of this memorandum of understanding has no impact on the Company's financial results at this time.
Items this document does not state (17)
Alliance partner's capitalAlliance partner's net salesAlliance partner's operating incomeNumber of shares acquiredAcquisition priceShareholding ratioOverview of the joint ventureOwnership ratioDispatch of directors and officersContract PeriodNumerical targets under the allianceShareholding PolicyDate of board resolutionContract DateAlliance start dateShare Acquisition Date and Payment DateChange in major shareholders

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To examine the potential for collaboration and the creation of business opportunities related to the research, development and manufacturing of antibody drugs, and to pursue further business growth by leveraging the strengths of both companies.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of the Execution of a Memorandum of Understanding with EirGenix, Inc. to Explore Collaboration on Antibody Drugs | Perseus Proteomics Inc. (4882) timely disclosure | Komori